Elosulfase Alfa (Vimizim®)

IMPORTANT REMINDER

We develop Medical Policies to provide guidance to Members and Providers. This Medical Policy relates only to the services or supplies described in it. The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed. If there is a conflict between the medical policy and a health plan or government program (e.g., TennCare), the express terms of the health plan or government program will govern.

POLICY

INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications
Vimizim is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA, Morquio A syndrome).

All other indications are considered experimental/investigational and not medically necessary.

DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review:
Initial Requests:

- N-acetylgalactosamine 6-sulfatase enzyme assay or genetic testing results supporting diagnosis.
- Chart notes or medical records documenting clinical signs and symptoms of disease at baseline (e.g., kyphoscoliosis, genu valgum, pectus carinatum, respiratory compromise, valvular heart disease, hearing impairment, corneal clouding, hepatomegaly, neurologic impairment).

Continuation Requests:

- Chart notes documenting a clinically positive response to therapy, which shall include improvement, stabilization, or slowing of disease progression (e.g., improvement, stabilization, or slowing of disease progression for 6-minute walk test, 3-minute stair climb, urine keratan sulfate levels).

PRESCRIBER SPECIALTIES

This medication must be prescribed by or in consultation with a physician who specializes in the treatment of metabolic disease and/or lysosomal storage disorders.

COVERAGE CRITERIA

Mucopolysaccharidosis IVA (MPS IVA, Morquio A syndrome)

Authorization of 12 months may be granted for treatment of MPS IVA (Morquio A syndrome) when both of the following criteria are met:

- The diagnosis of MPS IVA was confirmed by enzyme assay demonstrating a deficiency of N-acetylgalactosamine 6-sulfatase enzyme activity or by genetic testing.

- Member exhibits clinical signs and symptoms of disease at baseline (e.g., kyphoscoliosis, genu valgum, pectus carinatum, respiratory compromise, valvular heart disease, hearing impairment, corneal clouding, hepatomegaly, neurologic impairment).

CONTINUATION OF THERAPY

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the Coverage Criteria section who have a clinically positive response to therapy, which shall include improvement, stabilization, or slowing of disease progression (e.g., improvement, stabilization, or slowing of disease progression for 6-minute walk test, 3-minute stair climb, urine keratan sulfate levels).

MEDICATION QUANTITY LIMITS

Drug Name	Diagnosis	Maximum Dosing Regimen
Vimizim (Elosulfase alfa)	Mucopolysaccharidosis IVA (MPS IVA, Morquio A Syndrome)	Route of Administration: Intravenous 2mg/kg every week

APPLICABLE TENNESSEE STATE MANDATE REQUIREMENTS

BlueCross BlueShield of Tennessee's Medical Policy complies with Tennessee Code Annotated Section 56-7-2352 regarding coverage of off-label indications of Food and Drug Administration (FDA) approved drugs when the off-label use is recognized in one of the statutorily recognized standard reference compendia or in the published peer-reviewed medical literature.

ADDITIONAL INFORMATION

For appropriate chemotherapy regimens, dosage information, contraindications, precautions, warnings, and monitoring information, please refer to one of the standard reference compendia (e.g., the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) published by the National Comprehensive Cancer Network®, Drugdex Evaluations of Micromedex Solutions at Truven Health, or The American Hospital Formulary Service Drug Information).

REFERENCES

1. Vimizim [package insert]. Novato, CA: BioMarin Pharmaceutical Inc.; October 2025.
2. Hendriksz CJ, Berger KI, Giugliani R, et al. International guidelines for the management and treatment of Morquio A syndrome. Am J Med Genet A. 2015;167A(1):11-25.
3. Regier DS, Oetgen M, Tanpaiboon P. Mucopolysaccharidosis Type IVA. 2013 Jul 11 [Updated 2021 Jun 17]. In: Adam MP, Bick S, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026.

EFFECTIVE DATE **10/31/26**